Xenetic Biosciences Inc (NASDAQ:XBIO) Short Interest Update

Xenetic Biosciences Inc (NASDAQ:XBIO) saw a significant growth in short interest in the month of January. As of January 15th, there was short interest totalling 10,100 shares, a growth of 1,920.0% from the December 31st total of 500 shares. Based on an average daily volume of 21,600 shares, the days-to-cover ratio is currently 0.5 days. Approximately 0.8% of the shares of the company are sold short.

Xenetic Biosciences Price Performance

Shares of XBIO traded up $0.00 during trading hours on Tuesday, hitting $4.15. The stock had a trading volume of 1,578 shares, compared to its average volume of 7,181. The firm has a 50 day simple moving average of $4.17 and a 200-day simple moving average of $4.00. Xenetic Biosciences has a 1-year low of $2.78 and a 1-year high of $5.20. The firm has a market capitalization of $6.39 million, a P/E ratio of -1.56 and a beta of 2.22.

Xenetic Biosciences (NASDAQ:XBIO) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.14). The firm had revenue of $0.61 million for the quarter, compared to the consensus estimate of $0.75 million. Xenetic Biosciences had a negative net margin of 161.63% and a negative return on equity of 49.51%. Equities analysts predict that Xenetic Biosciences will post -1.01 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “neutral” rating on shares of Xenetic Biosciences in a research report on Thursday, December 5th.

Xenetic Biosciences Company Profile

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.